Document Detail

Results of the self-expandable BA9 stent for treatment of large angle coronary bifur-cation.
MedLine Citation:
PMID:  24500214     Owner:  NLM     Status:  In-Data-Review    
Since the advent of coronary angioplasty the treatment of bifurcation lesions has always proved a complex issue resulting in lower angiographic success rates, increased risk of restenosis, higher rates of dissection, myocardial infarction, and acute vessel closure. The advent of coronary stenting reduced the risks, but in-stent restenosis was noted to be frequent at the ostium of the side branch; for this reasons two-stent techniques were developed to try to combat this phenomenon. Novel dedicated stents have recently been developed to provide easier access to the SB and to scaffold more effectively its ostium, matching the stent configuration more closely to the anatomy of the bifurcation. Most of bifurcation lesions that require treatment and which have a wide angle involving the left main coronary artery (LMCA). The impact of the angle and the asymmetry of bifurcation on flow dynamic are very important and may influence clinical outcome. More recently, percutaneous coronary intervention (PCI) to treat wide angle disease has increased in frequency, and is associated with improvements in interventional techniques and adjunctive drug therapy. Several studies have shown that stenting in LMCA, especially using drug-eluting stents (DES), is a safe and effective treatment strategy both at mid- and long-term follow-up. The AXXESS System is a self-expanding, conically-shaped stent from nitinol (nickel-titanium alloy) with strut thickness, specifically designed to conform to the anatomy at the level of the bifurcation carina. A special version of the AXXESS System has been designed for left main bifurcation lesions, allowing for larger diameters (up to 4.75 mm) and distinct bifurcation angles (flare-end diameters of 8, 10 and 12 mm). The AXXENT trial is the first study to evaluate the vascular response of the self-expanding biolimus-eluting AXXESS stent for the treatment of LMCA bifurcation lesions. It was designed to evaluate the safety and efficacy of the AXXESS biolimus-eluting stent for the treatment of LMCA bifurcation lesions, that showed good results in terms of stent thrombosis and TLR at 6 months follow-up. Technical modifications and stent innovations may further improve both the angiographic and clinical outcomes for patients with wide angle bifurcation disease treated by PCI. Moreover a long term follow-up is needful to demonstrate better safety and efficacy of these new dedicated bifurcation devices.
L Lucisano; S Calcagno; M Pennacchi; R E Stio; M Mancone; G Sardella
Related Documents :
20583954 - The effect of age on the efficacy of human mesenchymal stem cell transplantation after ...
17028164 - Ang ii type 1a receptor signaling causes unfavorable scar dynamics in the postinfarct h...
16554734 - Myocardial apoptosis associated with the expression of proinflammatory cytokines during...
15385154 - Cellular recruitment and the development of the myocardium.
19487234 - Distinct myocardial effects of beta-blocker therapy in heart failure with normal and re...
6191294 - Horizontal and longitudinal dissociation of the a-v node during atrial tachycardia.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Minerva cardioangiologica     Volume:  62     ISSN:  1827-1618     ISO Abbreviation:  Minerva Cardioangiol     Publication Date:  2014 Feb 
Date Detail:
Created Date:  2014-02-06     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0400725     Medline TA:  Minerva Cardioangiol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  19-27     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Impact of drug-eluting stent generation on patient- and stent-related adverse events of diabetic pat...
Next Document:  The role of MGuard stent in primary coronary angioplasty.